U
3.40
-0.35 (-9.22%)
| Penutupan Terdahulu | 3.74 |
| Jumlah Dagangan | 1,327,856 |
| Harga / Pendapatan (P/E Ke hadapan) | 2.07 |
| Harga / Buku (P/B) | 1.96 |
| Julat 52 Minggu |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 4.86% |
| Nisbah Semasa (MRQ) | 1.64 |
| Aliran Tunai Operasi (OCF TTM) | -31.02 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -35.41 M |
| Pulangan Atas Aset (ROA TTM) | -48.08% |
| Pulangan Atas Ekuiti (ROE TTM) | -92.09% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Unicycive Therapeutics, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 3.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -2.5 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | -1.1 |
| Persekitaran Makro | -2.8 |
| AI Insight | NA |
| AI Technical | NA |
| Purata | -0.97 |
|
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 4.93% |
| % Dimiliki oleh Institusi | 49.60% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| J. Goldman & Co Lp | 30 Jun 2026 | 327,345 |
| Diadema Partners Lp | 30 Jun 2026 | 303,676 |
| Dauntless Investment Group, Llc | 30 Jun 2026 | 214,000 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |